Charles River Laboratories International (NYSE:CRL – Get Free Report) was downgraded by analysts at Zacks Research from a “strong-buy” rating to a “hold” rating in a research report issued on Monday, Zacks reports.
Other analysts have also recently issued research reports about the company. Deutsche Bank Aktiengesellschaft upped their price target on Charles River Laboratories International from $300.00 to $320.00 and gave the stock a “buy” rating in a research report on Friday, September 25th. UBS Group began coverage on Charles River Laboratories International in a research report on Wednesday, September 30th. They set a “buy” rating and a $357.00 price objective on the stock. Piper Sandler set a $300.00 price objective on Charles River Laboratories International in a research report on Monday, August 10th. Royal Bank Of Canada boosted their price objective on Charles River Laboratories International from $282.00 to $322.00 and gave the company an “outperform” rating in a research note on Friday, September 25th. Finally, Argus set a $330.00 target price on shares of Charles River Laboratories International in a report on Thursday, September 17th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Charles River Laboratories International currently has an average rating of “Moderate Buy” and an average price target of $302.33.
Get Our Latest Analysis on CRL
Charles River Laboratories International Trading Up 3.5%
Shares of CRL stock opened at $350.30 on Monday. Charles River Laboratories International has a 1 year low of $146.20 and a 1 year high of $379.63. The firm has a fifty day moving average price of $303.97 and a 200-day moving average price of $223.61. The company has a debt-to-equity ratio of 0.92, a current ratio of 1.35 and a quick ratio of 1.04. The company has a market cap of $16.72 billion, a price-to-earnings ratio of -72.23, a PEG ratio of 3.16 and a beta of 1.36.
Charles River Laboratories International (NYSE:CRL – Get Free Report) last posted its quarterly earnings data on Wednesday, November 4th. The medical research company reported $3.09 EPS for the quarter, topping the consensus estimate of $2.97 by $0.12. Charles River Laboratories International had a positive return on equity of 15.75% and a negative net margin of 5.96%. The firm had revenue of $982.73 million during the quarter, compared to analyst estimates of $960.36 million. As a group, equities analysts predict that Charles River Laboratories International will post 11.38 earnings per share for the current year.
Insider Buying and Selling
In other Charles River Laboratories International news, CAO Michael Knell sold 6,645 shares of the firm’s stock in a transaction dated Thursday, August 6th. The stock was sold at an average price of $260.38, for a total transaction of $1,730,225.10. Following the sale, the chief accounting officer directly owned 11,852 shares of the company’s stock, valued at $3,086,023.76. This trade represents a 35.92% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Shannon M. Parisotto sold 3,714 shares of the business’s stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $279.66, for a total value of $1,038,657.24. Following the completion of the transaction, the executive vice president owned 4,807 shares in the company, valued at $1,344,325.62. The trade was a 43.59% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 113,123 shares of company stock worth $33,864,118 in the last three months. Corporate insiders own 1.30% of the company’s stock.
Institutional Trading of Charles River Laboratories International
Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Physician Wealth Advisors Inc. lifted its holdings in Charles River Laboratories International by 127.9% in the 3rd quarter. Physician Wealth Advisors Inc. now owns 98 shares of the medical research company’s stock worth $29,000 after purchasing an additional 55 shares in the last quarter. Continuum Advisory LLC purchased a new stake in Charles River Laboratories International during the 2nd quarter valued at approximately $30,000. IFP Advisors Inc grew its holdings in Charles River Laboratories International by 182.8% during the 3rd quarter. IFP Advisors Inc now owns 164 shares of the medical research company’s stock valued at $48,000 after buying an additional 106 shares in the last quarter. Compass Wealth Management LLC bought a new stake in shares of Charles River Laboratories International during the third quarter valued at approximately $69,000. Finally, Activest Wealth Management raised its position in shares of Charles River Laboratories International by 25.9% during the third quarter. Activest Wealth Management now owns 277 shares of the medical research company’s stock valued at $82,000 after buying an additional 57 shares during the last quarter. Institutional investors own 98.91% of the company’s stock.
Charles River Laboratories International Company Profile
Charles River Laboratories International, Inc is a contract research and laboratory services company that supports pharmaceutical, biotechnology, medical device and academic research organizations. The company provides products and services used throughout the drug-development process, from early discovery and research through preclinical testing and manufacturing support.
Its offerings include research models, laboratory animal management, discovery and safety assessment services, toxicology testing, bioanalysis, and support for biologic, cell and gene therapy programs.
Read More
- Five stocks we like better than Charles River Laboratories International
- Shopify’s Small Q3 Miss Triggered a Big Sell-Off: What’s Next?
- Can Oil’s Big Rally Deliver Reliable Income? 3 Energy Plays to Watch
- Marriott’s Earnings Beat Shows Why It’s More Than a Bet on Travel Demand
- Franklin Templeton’s New ETFs Turn Stock Dividends Into Bitcoin—What’s the Catch?
Receive News & Ratings for Charles River Laboratories International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International and related companies with MarketBeat.com's FREE daily email newsletter.
